Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite b

Go online to PeerView.com/HWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care. Upon completion of this activity, participants should be better able to: Summarize the s

Go online to PeerView.com/WFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent unique, potent, and promising new options in the lung cancer treatment arsenal. Ongoing clinical trials evaluating ADCs, including those directed at trophoblast cell surface antigen 2 (TROP2), have demonstrated positive preliminary data in lung cancer, and additional results from other studies assessing monotherapy and rational combinatorial options are anticipated in the near future. As advances with TROP2-targeting ADCs continue, it is crucial for oncologists and other professionals involved in the care of patients with lung cancer to gain knowledge of the rationale, characteristics, efficacy, and different adverse event profiles of these novel therapies. They must also develop the necessary skills to enable rapid adoption of these therapies into their clinical practice should they receive regulatory approval. This educational activity

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeut

Go online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-B

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, a

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes th

Go online to PeerView.com/NYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in fibrodysplasia ossificans progressiva (FOP) discuss the pathophysiology, prevalence, and burden of the disease, as well as the disease’s manifestations and common misdiagnoses. With a focus on improving patient care and quality of life, the activity also includes a patient interview and 3D animation and is part of a larger education collection on FOP. Upon completion of this activity, participants should be better able to: Describe the mechanism of disease of FOP, including the underlying genetic pathophysiology; Summarize the spectrum of FOP disease manifestations, understanding the holistic burden on the patient and impact on quality of life; and Avoid iatrogenic harm caused by diagnostic errors by correctly identifying patients with the clinical hallmarks of FOP

Go online to PeerView.com/NJA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP. Upon completion of this activity, participants should be better able to: Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations; Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis; Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action; and Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach

Go online to PeerView.com/XZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the United States, the prevalence of obesity has been steadily increasing. Despite the number of obesity specialists in the United States multiplying five-fold from 2011 to 2019, there is an inadequate number of trained professionals to treat all people requiring obesity-targeted care. Primary care is often the first and only touch point for many people with obesity (PwO), and there is a need to equip and prepare primary care professionals (PCPs) to treat this patient population with empathetic, effective, and evidence-based obesity-targeted care. This PeerView Train-the-Trainer MasterClass activity combines concise overviews of essential evidence with training resources to help you, as an obesity specialist, lead the charge to educate your PCP colleagues. Using practical exercises, experts provide guidance on strategies and tactics you can use to create your own training wor

Go online to PeerView.com/SFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new PeerView activity based on a recorded symposium at the 75th Annual Bleeding Disorders Conference, an expert panel engages in thought-provoking, interactive case-based discussions and offers guidance on how healthcare professionals can address real-world challenges of hemophilia A management with novel EHL FVIII prophylaxis. Our experts provide guidance on critically evaluating the latest clinical evidence, tailoring treatment plans to individual patient needs, and navigating the challenges associated with patient adherence, access to therapy, and transitioning patients from conventional options (eg, SHL FVIII replacement therapy) to innovative EHL FVIII prophylaxis. Access this activity now to see if you are prepared to lead the way to better outcomes for hemophilia A! Upon completion of this activity, participants should be better able to: Summarize the mechanistic

Go online to PeerView.com/PQU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox! Upon completion of this activity, participants should be better able to: Intens

Go online to PeerView.com/EEG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple professional societies have emphasized the importance of lowering LDL-C for the primary and secondary prevention of ASCVD and cardiovascular events. Though current guidelines recommend statins as the cornerstone of lipid-lowering therapies, many patients have insufficient response or intolerance to them and require non-statin therapies to achieve their individualized LDL-C goals. Enter PCSK9-targeting therapies! This CME activity shares current gaps in hyperlipidemia care, offers strategies for meeting these unmet needs, and presents the latest clinical data for PCSK9-targeting agents. An in-depth patient case example helps to illustrate the importance of screening and ASCVD risk assessment, how to initiate therapy with novel strategies, and best practices for improving hyperlipidemia management to help more patients achieve their goals. Upon completion of this activity

Go online to PeerView.com/QVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. After almost two decades without a new AD treatment, recent advances in disease-modifying therapies—including the accelerated FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have introduced the possibility of slowed disease progression and improved patient outcomes. Furthermore, significant advances have been made in identifying and testing biomarkers for AD that may aid in early diagnosis, proper treatment selection, and assessment of therapeutic response. The latter is increasingly important given the need to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia. With the rapid deve

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable

Go online to PeerView.com/UTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care. Upon completi

Go online to PeerView.com/ZAB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of recombinant human growth hormone (rhGH) therapy has facilitated wider treatment of growth hormone deficiency. In this CME-certified MasterClass & Practicum video activity, expert faculty will review current guidelines for pediatric growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. Tune in today to increase your knowledge and competence on the diagnosis and management of growth hormone deficiency with rhGH therapy, including long-acting growth hormone agents, and gain a better understanding of how to address patient needs. Upon completion of this activity, participants should be better able to: Utilize relevant diagnostic tests to provide timely diagnosis of pediatric patients suspected to have growth hormone deficiency; Compare the clinical characteristics and s

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, particip

Go online to PeerView.com/MVQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials. Upon completion of this activity, participants should be better able to: Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors; Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs; and Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK